Wall Street analysts expect that Nektar Therapeutics (NASDAQ:NKTR) will post earnings of ($0.69) per share for the current fiscal quarter, Zacks Investment Research reports. Seven analysts have provided estimates for Nektar Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.75) and the highest estimate coming in at ($0.56). Nektar Therapeutics reported earnings per share of ($0.57) during the same quarter last year, which would indicate a negative year-over-year growth rate of 21.1%. The business is expected to issue its next quarterly earnings results on Thursday, February 27th.
According to Zacks, analysts expect that Nektar Therapeutics will report full year earnings of ($2.56) per share for the current fiscal year, with EPS estimates ranging from ($2.60) to ($2.43). For the next fiscal year, analysts anticipate that the business will report earnings of ($2.48) per share, with EPS estimates ranging from ($3.00) to ($1.85). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that cover Nektar Therapeutics.
Nektar Therapeutics (NASDAQ:NKTR) last issued its earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.73) by $0.17. The firm had revenue of $29.22 million for the quarter, compared to the consensus estimate of $26.42 million. Nektar Therapeutics had a negative return on equity of 26.60% and a negative net margin of 352.83%. The company’s revenue was up 5.3% compared to the same quarter last year. During the same quarter last year, the business posted ($0.56) EPS.
A number of brokerages have weighed in on NKTR. HC Wainwright reaffirmed a “hold” rating and issued a $32.00 target price on shares of Nektar Therapeutics in a report on Friday, January 10th. William Blair reaffirmed a “buy” rating on shares of Nektar Therapeutics in a report on Thursday, September 26th. Piper Jaffray Companies reduced their target price on Nektar Therapeutics from $50.00 to $35.00 and set an “overweight” rating on the stock in a report on Thursday, November 7th. Oppenheimer began coverage on Nektar Therapeutics in a report on Thursday, October 24th. They issued a “market perform” rating and a $18.00 target price on the stock. Finally, Goldman Sachs Group cut Nektar Therapeutics from a “buy” rating to a “sell” rating and dropped their price target for the company from $54.00 to $16.00 in a research note on Tuesday, October 8th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $30.43.
Shares of NKTR stock traded down $1.42 during trading hours on Friday, reaching $22.48. The company’s stock had a trading volume of 3,476,639 shares, compared to its average volume of 4,283,517. The firm’s 50 day simple moving average is $21.90 and its 200-day simple moving average is $22.09. The company has a market capitalization of $4.20 billion, a price-to-earnings ratio of 5.95 and a beta of 2.60. Nektar Therapeutics has a fifty-two week low of $15.64 and a fifty-two week high of $47.11. The company has a quick ratio of 12.49, a current ratio of 12.60 and a debt-to-equity ratio of 0.26.
In other news, CEO Howard W. Robin sold 13,556 shares of the stock in a transaction on Monday, November 18th. The stock was sold at an average price of $17.97, for a total value of $243,601.32. Following the completion of the transaction, the chief executive officer now directly owns 299,219 shares in the company, valued at approximately $5,376,965.43. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Gil M. Labrucherie sold 25,000 shares of the stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $19.79, for a total value of $494,750.00. The disclosure for this sale can be found here. Insiders sold a total of 54,092 shares of company stock valued at $1,017,533 over the last quarter. 4.02% of the stock is owned by corporate insiders.
Institutional investors and hedge funds have recently made changes to their positions in the company. CSat Investment Advisory L.P. raised its position in Nektar Therapeutics by 54.3% during the 2nd quarter. CSat Investment Advisory L.P. now owns 2,071 shares of the biopharmaceutical company’s stock worth $74,000 after purchasing an additional 729 shares during the last quarter. Liberty Wealth Management LLC raised its position in Nektar Therapeutics by 1,402.6% during the 3rd quarter. Liberty Wealth Management LLC now owns 2,870 shares of the biopharmaceutical company’s stock worth $52,000 after purchasing an additional 2,679 shares during the last quarter. Atria Investments LLC bought a new position in Nektar Therapeutics during the 2nd quarter worth $240,000. Barings LLC bought a new position in Nektar Therapeutics during the 2nd quarter worth $213,000. Finally, Verition Fund Management LLC bought a new position in Nektar Therapeutics during the 2nd quarter worth $254,000. Institutional investors own 99.77% of the company’s stock.
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology.
Read More: Guidelines for Successful Channel Trading
Get a free copy of the Zacks research report on Nektar Therapeutics (NKTR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.